TARA News and Press, ArTara Therapeutics Inc. From 02/02/23

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare ...

Protara Therapeutics ( NASDAQ: TARA ) appoints Patrick Fabbio as CFO effective January 30, 2023. Mr. Fabbio most recently served as President and CFO at NYSE-listed Rafael. “We are excited to welcome Pat to the Protara leadership team. With his impressive...

NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Patrick Fabbio as Chief Financial Officer effective January 30, 202...

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 P...

ArTara Therapeutics press release ( NASDAQ: TARA ): Q3 GAAP EPS of -$0.68 beats by $0.08 . As of September 30, 2022, cash, cash equivalents and marketable debt securities were $107.1 million. The Company now expects its current cash and cash equivalents will be suffici...

- Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Administration, Phase 2 Study of TARA-002 in Lymphatic Malformations Expected to Initiate in 2023 -...

Summary We put small biopharma concern Protara Therapeutics in the spotlight today for the first time in more than 18 months. The stock has seen some small insider buying throughout 2022 and the shares sell for less than 50% of the company's net cash on the balance sheet. An i...

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 24th Annual Global Inv...

- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash Equivalents and Investments Position of $112.8M as of June 30, 2022 Expected to Fund Operations into Mid-2024 - NEW YORK, Aug. 09,...

Protara Therapeutics (TARA) has announced that its CFO, Blaine Davis, will be leaving to pursue other opportunities and his last day will be July 15, 2022. Mr. Davis’ departure is not related to Protara’s operations, financial reporting or controls. As of March 31, 2022, th...